Document:

Exhibit 10.17

                            PLACEMENT AGENT AGREEMENT

                          Dated as of: August 21, 2003

Meyers Associates, L.P.
45 Broadway
New York, New York 10006

Ladies and Gentlemen:

      The undersigned, InforMedix, Inc. (the "Company"), hereby agrees with
Meyers Associates, L.P. ("MA") as follows:

1.       Offerings.

         A. The Company hereby engages MA to act as its exclusive placement
agent in connection with the following:

                  (i) issuance and sale by the Company (the "Bridge Financing")
of between four (4) and eight (8) units of the Company (the "Bridge Units"),
each Bridge Unit consisting of $50,000 principal amount of 10% promissory notes
and one warrant (the "Bridge Warrant") to purchase 100,000 shares of the
Company's common stock (the "Common Stock"), expiring on the fifth anniversary
of the date of issuance, at an exercise price of the lower of (A) $0.50 per
share and (B) the average bid price (calculated to the nearest $.0001) of the
Common Stock for the five (5) consecutive trading days immediately preceding and
including the second trading day immediately prior to the Note Purchase Closing
(as hereinafter defined); and

                  (ii) issuance and sale by the Company (the "Private Placement
Offering") of up to 5,000,000 units (the "Private Placement Units") of the
Company, each Private Placement Unit consisting of one share (the "Share") of
the Company's Common Stock and one A Warrant and one B Warrant, as defined
below, at a price anticipated to be the lower of (A) $0.50 per Unit and (B) the
average bid price (calculated to the nearest $.0001) of the Common Stock for the
five (5) consecutive trading days immediately preceding and including the second
trading day immediately prior to the Closing (the "Offering Price"). In the
event that MA determines that adverse market conditions would preclude the
Offering Price contemplated herein, MA and the Company shall negotiate in good
faith to determine an appropriate offering price. Each A warrant (the "A
Warrant") entitles the holder to purchase one share of Common Stock at any time
after issuance at an exercise price per A Warrant determined as follows: (1) if
the Offering Price is higher than $0.50, the exercise price per A Warrant shall
equal the lower of (A) $0.60 and (B) 120% of the Offering Price; (2) if the
Offering Price is equal to $0.50, the exercise price per A Warrant shall equal
$0.60; and (3) if the Offering Price is lower than $0.50, the exercise price per
A Warrant shall equal the lower of (A) $.50 and (B) 120% of the Offering Price.
The A warrants shall expire on the fifth anniversary of the date of issuance and
be subject to other terms and conditions set forth in the A Warrant Agreement
dated the date of the Closing (as hereinafter defined). Each B warrant (the "B
Warrant") entitles the holder to purchase one-half of one share of Common Stock
at any time after issuance at an exercise price determined as follows: (1) if
the Offering Price is higher than $0.50, the exercise price per B Warrant shall
equal the lower of (A) $0.375 and (B) 75% of the Offering Price; (2) if the
Offering Price is equal to $0.50, the exercise price per B Warrant shall equal
$0.375; and (3) if the Offering Price is lower than $0.50, the exercise price
per B Warrant shall equal the lower of (A) $0.25 and (B) 75% of the Offering
Price. The B warrants shall expire on the fifth anniversary of the date of
issuance and be subject to other terms and conditions set forth in the B Warrant
Agreement dated the date of the Closing.

<PAGE>

The Bridge Warrants, the A Warrants and the B Warrants are sometimes
collectively referred to herein as the "Warrants". The Bridge Units and the
Private Placement Units are sometimes collectively referred to herein as the
"Units". The Bridge Financing and the Private Placement Offering are sometimes
collectively referred to herein as the "Offering".

         B. The Private Placement Units will be offered pursuant to the
Confidential Private Offering Memorandum prepared by the Company (such
memorandum together with all amendments thereof and supplements and exhibits
thereto, and documents incorporated therein, is referred to herein as the
"Memorandum") and are subject to the terms and conditions set forth therein, and
in the Subscription Agreement (collectively, the "Subscription Agreements") in
substantially the form of exhibits attached to the Memorandum to be executed by
each purchaser and the Company.

         C. At the Note Purchase Closing (as defined in Section 1(F) hereof),
the Company shall also issue and sell to MA and/or its designees for an
aggregate purchase price of $10 a warrant to purchase that number of shares of
Common Stock (together with the shares of common stock underlying the other
warrant to be issued to MA described in this Section 1(C), the "Placement
Agent's Shares") equal to the quotient obtained by dividing 30% of the gross
proceeds from the sale of the Bridge Units by the exercise price per share for a
Bridge Warrant determined in accordance with Section 1(A)(i) above, under terms
and conditions set forth in the Placement Agent's Warrant Agreement dated the
date of the Closing. The terms of the Placement Agent Warrant to be issued at
the Note Purchase Closing will be identical to the terms contained in the Bridge
Warrants except the Placement Agent Warrant shall contain a cash-less exercise
provision. At the Closing (as defined in Section 1(F) hereof), the Company shall
also issue and sell to MA and/or its designees for an aggregate purchase price
of $10 a warrant to purchase that number of shares of Common Stock equal to 30%
of the aggregate number of Private Placement Units sold in the Offering
(together with the Placement Agent Warrant described above in this Section 1(C),
the "Placement Agent's Warrants"), under terms and conditions set forth in the
Placement Agent's Warrant Agreement dated the date of the Closing. The terms of
the Placement Agent's Warrant to be issued at the Closing will be identical to
the terms contained in the A Warrants except the Placement Agent Warrant shall
contain a cash-less exercise provision.

                                       2
<PAGE>

The Placement Agent's Warrants and the Placement Agent's Shares are sometimes
hereinafter collectively referred to as the "Placement Agent's Securities." The
Units, the Warrants, the Shares, the Placement Agent's Securities and the Common
Stock issuable upon exercise of the Warrants and the Placement Agent's Warrants
are hereinafter sometimes collectively referred to as the "Securities."

         D. The Units (including the Common Stock underlying the Warrants) and
the Placement Agent's Shares (including the Common Stock underlying the
Placement Agent's Warrants) will be offered without registration under the
Securities Act of 1933, as amended (the "Securities Act"). Purchasers of the
Units and MA will be granted certain registration rights with respect to the
Shares and the Common Stock issuable upon exercise of the Warrants as more fully
set forth in their respective Registration Rights Agreements.

         E. The Units will be offered by MA on a "best efforts, minimum-maximum"
basis consisting of: (i) a minimum amount of $200,000 and a maximum amount of
$400,000 for the Bridge Financing and (ii) a minimum amount of $1,000,000 and a
maximum amount of $5,000,000 for the Private Placement Offering.

         F.       Closings.

                  (i) The Company will issue the Bridge Units at the Closing (as
defined in the Note Purchase Agreement by and between the Company and the
Investors named therein, dated as of August 21, 2003 (the "Note Purchase
Agreement") (the "Note Purchase Closing"), and in the manner provided for in the
Note Purchase Agreement; and

                  (ii) The Company will issue the Private Placement Units at the
Closing after subscriptions have been received and accepted by the Company and
when funds from investors have cleared the banking system in the normal course
of business. The issuance of the Units and disbursement of the proceeds from the
sale thereof (the "Closings") will occur promptly after (i) the date on which
$1,500,000 of subscription proceeds for Units has cleared the banking system and
has been collected by the Escrow Agent (as defined in Section 2(C) hereof)
pursuant to the Escrow Agreement (as defined in Section 2(C)) and (ii)
thereafter within five (5) business days of notice from MA.

         G. The Private Placement Offering shall commence on the date that the
Company delivers the final Memorandum to MA (the "Memorandum Completion Date")
and shall terminate 90 days thereafter if the minimum is not sold in the Private
Placement Offering, unless extended by the mutual consent of the Company and MA.
If the minimum is sold in the Private Placement Offering by the 90th day after
the Memorandum Completion Date, then the Offering will terminate 120 days after
the Memorandum Completion Date, unless extended by the mutual consent of the
Company and MA (such date, as the same may be extended, is hereinafter referred
to as the "Termination Date"; the period commencing on the Memorandum Completion
Date and ending on the Termination Date is sometimes referred to herein as the
"Offering Period").

                                       3
<PAGE>

2.       Information.

         A.       Offering Period.

                  The Units will be offered by MA on a "best efforts" basis
during the Offering Period. Throughout the Private Placement Offering, MA shall
not offer the Private Placement Units or any other restricted securities of the
Company to any person who is engaged in any business which is competitive with
the business of the Company, either on his own behalf or as an officer,
director, stockholder, partner, principal, trustee, investor, consultant,
associate, employee, owner, agent, creditor, independent contractor, co-venturer
of any other business, firm, corporation, partnership or other entity or in any
other relationship or capacity ("Company Competing Businesses"). Company
Competing Businesses shall include any business or line of business currently
conducted or engaged in by the Company, or which is conducted or engaged in by
the Company, at the time the securities are offered by MA on the Company's
behalf.

         B. The Private Placement Units shall have the terms set forth in and
shall be offered by the Company by means of the Memorandum. Payment for the
Units shall be made by check or wire transfer as more fully described in the
Subscription Agreements. The minimum purchase by any purchaser of Bridge Units
shall be $50,000 unless subscriptions for fewer Bridge Units are accepted at the
discretion of MA. The minimum purchase by any purchaser of Private Placement
Units shall be $100,000 unless subscriptions for fewer Private Placement Units
are accepted at the discretion of MA. MA and the Company agree that the Units
will be offered and sold only to "accredited investors" within the meaning of
Rule 501 of Regulation D ("Accredited Investors") promulgated by the Securities
and Exchange Commission (the "Commission") under the Securities Act and Rule 506
of Regulation D of the Securities Act.

         C. All funds received from subscriptions will be promptly transmitted
pursuant to the terms of an escrow agreement (the "Escrow Agreement") to the
escrow account designated for the Offering at United Bank, Inc. (the "Escrow
Agent"). In the event that the Note Purchase Closing occurs, the funds received
in respect of the Units closed on will be forwarded to the Company net of (i)
the placement agent commission equal to ten percent (10%) of the gross proceeds
from the sale of the Units, (ii) the placement agent's non-accountable expense
allowance equal to three percent (3%) of the gross proceeds from the sale of the
Units, (iii) legal fees and expenses of MA's counsel, (iv) "Blue Sky" fees and
expenses and legal fees and expenses due to the Company's counsel; and (v) all
other expenses related to the Offering, including, but not limited to, due
diligence expenses related to meetings with potential investors not to exceed
$10,000, and all printing, duplication and mailing costs related to the
Memorandum, registration and transfer agent fees, escrow agent fees, accounting
fees, and issue and transfer taxes and "tombstone" expenses not to exceed
$5,000. The Company will advance $50,000 to MA towards the payment of the 3%
non-accountable expense allowance upon the Note Purchase Closing if gross
proceeds of $300,000 or more are received as a result of the Bridge Financing.
Such advance shall be prorated if gross proceeds of $200,000 or more, but less
than $300,000, are received as a result of the Bridge Financing.

                                       4
<PAGE>

         D. At each of the Note Purchase Closing and the Closing, the Company
shall cause to be paid by, at the option of MA, certified or official bank check
or wire transfer to MA, to the extent not previously paid by the Company or the
Escrow Agent to MA, (i) the placement agent commission equal to 10% of the gross
proceeds from the sale of the Bridge Units or the Private Placement Units, as
the case may be, (ii) the placement agent's non-accountable expense allowance
equal to 3% of the gross proceeds from the sale of the Bridge Units or the
Private Placement Units, as the case may be, (iii) legal fees and expenses of
MA's counsel, (iv) "Blue Sky" fees and expenses and legal fees and expenses
related thereto due to the Company's counsel, and (v) all other expenses related
to the Offering, including, but not limited to, due diligence expenses, all
printing, duplication and mailing costs related to the Memorandum, registration
and transfer agent fees, escrow agent fees, accounting fees, and issue and
transfer taxes and "tombstone" expenses. In addition to the foregoing, the
Company shall be responsible for the fees and expenses identified in Sections 6,
7, and 9 hereof, which expenses shall not be deemed to be commissions.

         E. MA shall not be obligated to sell any Units and shall only be
obligated to offer the Units on a "best efforts" basis.

3.       Representations and Warranties of the Company.

         The Company represents, warrants and covenants as follows:

         A. The execution, delivery and performance of each of this Agreement,
the Note Purchase Agreement, the Subscription Agreements, Registration Rights
Agreement, the Placement Agent's Warrant Agreement, the Consulting Agreement (as
defined in Section 8(G)), the M&A Agreement (as defined in Section 8(H)) and the
Escrow Agreement have been or will be duly and validly authorized by the Company
and is, or with respect to the Note Purchase Agreement, the Subscription
Agreements and the Placement Agent's Warrant Agreement will be, a valid and
binding agreement of the Company, enforceable in accordance with their
respective terms, except to the extent that (a) the enforceability hereof or
thereof may be limited by bankruptcy, insolvency, reorganization, moratorium or
similar laws from time to time in effect and affecting the rights of creditors
generally, (b) the enforceability hereof or thereof is subject to general
principles of equity or (c) the indemnification provisions hereof or thereof may
be held to be violative of public policy. The Securities have been duly
authorized and, the Securities and the certificates representing such Securities
when issued and paid for in accordance with the Memorandum, this Agreement, the
Escrow Agreement, the Placement Agent's Warrant Agreement, the Note Purchase
Agreement and the Subscription Agreements, will be valid and binding obligations
of the Company, enforceable in accordance with their respective terms, except to
the extent that (a) the enforceability thereof may be limited by bankruptcy,
insolvency, reorganization, moratorium or similar laws from time to time in
effect and affecting the rights of creditors generally, and (b) the
enforceability thereof is subject to general principles of equity. All corporate
action required to be taken for the authorization, issuance and sale of the
Securities has been duly and validly taken by the Company.

                                       5
<PAGE>

         B. All issued and outstanding securities of the Company, have been duly
authorized and validly issued and are fully paid and non-assessable; the holders
thereof have no rights of rescission or preemptive rights with respect thereto
and are not subject to personal liability solely by reason of being security
holders; and none of such securities was issued in violation of the preemptive
rights of any holders of any security of the Company. The Company has (x)
20,000,000 shares of authorized Common Stock, of which 9,165,585 shares (of
which MA shall be the record and beneficial owner of 612,000 shares of Common
Stock and warrants to purchase an additional 87,334 shares of Common Stock) will
be issued and outstanding as of the date hereof and (y) 4,500,000 shares of
authorized preferred stock, none of which are issued and outstanding as of the
date hereof.

         C. The Securities have been duly authorized and, each of the Shares and
the shares issuable upon exercise of the Warrants and the Placement Agent's
Warrants in accordance with the terms thereof, will be validly issued,
fully-paid and non-assessable; the holders thereof will not be subject to
personal liability solely by reason of being such holders; such securities are
not and will not be subject to the preemptive rights of any holder of any
security of the Company.

         D. Each of the Company and the Subsidiaries (as defined herein) has
good and marketable title to, or valid and enforceable leasehold estates in, all
items of real and personal property necessary to conduct its business
(including, without limitation any real or personal property stated in the
Memorandum to be owned or leased by the Company), free and clear of all liens,
encumbrances, claims, security interests and defects of any material nature
whatsoever, except as set forth in the disclosure schedule attached hereto (the
"Disclosure Schedule").

         E. There is no litigation or governmental proceeding pending or, to the
best of the Company's knowledge, threatened against, or involving the properties
or business of the Company or any of the Subsidiaries, except as set forth in
the Memorandum.

         F. Each of the Company and its subsidiaries has been duly organized and
validly exists as a corporation in good standing under the laws of its
respective state of incorporation. None of the Company or any of its
subsidiaries owns or controls, directly or indirectly, an interest in any other
corporation, partnership, trust, joint venture or other business entity
disclosed except as disclosed in this subsection 3(F). Each of the Company and
its subsidiaries is duly qualified or licensed and in good standing as a foreign
corporation in each jurisdiction in which the character of its operations
requires such qualification or licensing and where failure to so qualify would
have a material adverse effect on the Company. Each of the Company and its
subsidiaries has all requisite corporate power and authority, and all material
and necessary authorizations, approvals, orders, licenses, certificates and
permits of and from all governmental regulatory officials and bodies (domestic
and foreign) to conduct its businesses (and proposed business) as described in
the Memorandum, and each of the Company and its subsidiaries is doing business
in material compliance with all such authorizations, approvals, orders,
licenses, certificates and permits and all foreign, federal, state and local
laws, rules and regulations concerning the business in which it is engaged. Any
disclosures in the Memorandum concerning the effects of foreign, federal, state
and local regulation on the Company's and each of its subsidiaries' businesses
as currently conducted and as contemplated are correct in all material respects
and do not omit to state a material fact. The Company has all corporate power
and authority to enter into this Agreement, the Note Purchase Agreement, the
Escrow Agreement, the Placement Agent's Warrant Agreement, the Consulting
Agreement, the M&A Agreement and the Subscription Agreements and to carry out
the provisions and conditions hereof and thereof, and all consents,
authorizations, approvals and orders required in connection herewith and
therewith have been obtained or will have been obtained prior to the Closing. No
consent, authorization or order of, and no filing with, any court, government
agency or other body is required by the Company for the issuance of the
Securities pursuant to the Memorandum, the Note Purchase Agreement, the
Placement Agent's Warrant Agreement, the Consulting Agreement, the M&A Agreement
or the Subscription Agreements, except pursuant to applicable federal and state
securities laws. The Company, since its inception, has not incurred any
liability arising from a violation by the Company of any of the provisions of
the Securities Act, the Securities Exchange Act of 1934, as amended (the
"Exchange Act") or the rules and regulations promulgated under the Securities
Act and the Exchange Act.

                                       6
<PAGE>

         G. There has been no material adverse change in the condition or
prospects of the Company or any of its subsidiaries, financial or otherwise,
since March 31, 2003, except as set forth in the Disclosure Schedule, and the
outstanding debt, the property and the business of each of the Company and its
subsidiaries conforms in all material respects to the descriptions thereof
contained in the Memorandum.

         H. Neither the Company nor any of its subsidiaries is in material
breach of, or in material default under, any term or provision of any material
indenture, mortgage, deed of trust, lease, note, loan or credit agreement or any
other material agreement or instrument evidencing an obligation for borrowed
money, or any other material agreement or instrument to which it is a party or
by which it or any of its properties may be bound or affected, except as set
forth in the Disclosure Schedule. Neither the Company nor any of its
subsidiaries is in material violation of any provision of its charter or bylaws
or in material violation of any franchise, license, permit, judgment, decree or
order, or in violation of any statute, rule or regulation. Neither the execution
and delivery of this Agreement, the Note Purchase Agreement, the Escrow
Agreement, the Subscription Agreements, the Placement Agent's Warrant Agreement,
the Consulting Agreement, the M&A Agreement nor the issuance and sale or
delivery of the Securities nor the consummation of any of the transactions
contemplated herein or in the Note Purchase Agreement, the Subscription
Agreements, the Escrow Agreement, the Placement Agent's Warrant Agreement, the
Consulting Agreement, the M&A Agreement nor the compliance by the Company with
the terms and provisions hereof or thereof, has conflicted with or will conflict
with, or has resulted in or will result in a breach of, any of the terms and
provisions of, or has constituted or will constitute a default under, or give to
others any right of termination, amendment, acceleration or cancellation of, or
has resulted in or will result in the creation or imposition of any lien, charge
or encumbrance upon any property or assets of the Company or pursuant to the
terms of any material indenture, mortgage, deed of trust, note, loan or credit
agreement or any other material agreement or instrument evidencing an obligation
for borrowed money, or any other material agreement or instrument to which the
Company or any of its subsidiaries may be bound or to which any of the property
or assets of the Company or any of its subsidiaries is subject except (a) where
such default, lien, charge, encumbrance or other occurrence would not have a
material adverse effect on the Company or any of its subsidiaries, and (b) as
described in the Disclosure Schedule; nor will such action result in any
violation of the provisions of the charter or the bylaws of the Company or any
of its subsidiaries or, assuming the due performance by MA of its obligations
hereunder, any statute or any order, rule or regulation applicable to the
Company or any of its subsidiaries of any court or of any foreign, federal,
state or other regulatory authority or other government body having jurisdiction
over the Company or any of its subsidiaries.

                                       7
<PAGE>

         I. The Securities, the Escrow Agreement, the Placement Agent's Warrant
Agreement, the Consulting Agreement, the M&A Agreement and the Subscription
Agreements conform in all material respects to all statements in relation
thereto contained in the Memorandum.

         J. Subsequent to the dates as of which information is given in the
Disclosure Schedule, and except as may otherwise be indicated or contemplated
herein, therein or in the Note Purchase Agreement, neither the Company nor any
of its subsidiaries has (a) issued any securities or incurred any liability or
obligation, direct or contingent, for borrowed money, or (b) entered into any
transaction other than in the ordinary course of business, or (c) declared or
paid any dividend or made any other distribution on or in respect of its capital
stock.

         K. There are no claims against the Company (other than pursuant to this
Agreement) for services in the nature of a finder's or origination fee with
respect to the sale of the Units arising from any agreement made by the Company,
except as set forth in the Disclosure Schedule.

         L. Except as disclosed in the Disclosure Schedule, each of the Company
and its subsidiaries owns or possesses, free and clear of all liens or
encumbrances and rights thereto or therein by third parties, the trademarks,
patents and patent applications necessary to conduct its business (including,
without limitation, any such rights described in the Memorandum as being owned
or possessed by the Company or any of its subsidiaries) and there is no claim or
action by any person pertaining to, or proceeding, pending or to the Company's
knowledge threatened, which challenges the exclusive rights of the Company or
any of its subsidiaries with respect to the trademarks, patents and patent
applications used in the conduct of the Company's or any of its subsidiaries
businesses (including, without limitation, any such rights described in the
Memorandum as being owned or possessed by the Company or any of its
subsidiaries) except any claim or action that would not have a material adverse
effect on the Company or any of its subsidiaries; and except as disclosed in the
Disclosure Schedule, none of the Company's or any of its subsidiaries' current
products, services or processes create infringement liability or will infringe
on United States patents currently held by any third party.

         M. Except as described in the Disclosure Schedule, neither the Company
nor any of its subsidiaries is currently under any obligation to pay royalties
or fees of any kind whatsoever to any third party with respect to any trademarks
or patents, or technology it uses, employs or intends to use or employ.

                                       8
<PAGE>

         N. Subject to the performance by MA of its obligations hereunder, the
Memorandum and the offer and sale of the Securities comply, and will continue to
comply up to the Termination Date, in all material respects with the
requirements of Rule 506 of Regulation D promulgated by the Commission pursuant
to the Securities Act and any other applicable federal and state laws, rules,
regulations and executive orders. Neither the Memorandum nor any amendment or
supplement thereto nor any documents prepared by the Company in connection with
the Offering will contain any untrue statement of a material fact or omit to
state any material fact required to be stated therein or necessary to make the
statements therein, in light of the circumstances under which they were made,
not misleading. All statements of material facts in the Memorandum are true and
correct as of the date of the Memorandum and will be true and correct on the
date of the Closing.

         O. Except as reflected in the financial statements included in the
Memorandum, and except as set forth in the Disclosure Schedule, all taxes which
are due and payable from the Company have been paid in full and neither the
Company nor any of its subsidiaries has any tax deficiency or claim outstanding
assessed or to the Company's knowledge proposed against it.

         P. The Company has timely filed all registration statements,
prospectuses, forms, reports and other documents required to be filed by it with
the Commission since January 1, 2000 (collectively, the "SEC Reports"). As of
the respective dates they were filed, (i) the SEC Reports were prepared in
accordance with the requirements of the Securities Act or the Exchange Act, as
the case may be, and (ii) none of the SEC Reports contained any untrue statement
of a material fact or omitted to state a material fact required to be stated
therein or necessary in order to make the statements made therein not
misleading. No subsidiary of the Company is required to file any form, report or
other document with the Commission.

         Q. The financial statements of the Company included in the Memorandum
fairly present the financial position of the Company at March 31, 2003; and such
financial statements have been prepared in conformity with generally accepted
accounting principles, consistently applied throughout the periods involved,
except for the absence of footnotes and normal year-end adjustments.

         R. None of the Company or any of its subsidiaries nor any of their
officers, directors, employees or agents, nor any other person acting on behalf
of the Company or any of its subsidiaries, has, directly or indirectly, given or
agreed to give any money, gift or similar benefit (other than legal price
concessions to customers in the ordinary course of business) to any customer,
supplier, employee or agent of a customer or supplier, or official or employee
of any governmental agency or instrumentality of any government (domestic or
foreign) or any political party or candidate for office (domestic or foreign) or
other person who is or may be in a position to help or hinder the business of
the Company or any of its subsidiaries (or assist it in connection with any
actual or proposed transaction) which (i) might subject the Company or any of
its subsidiaries to any damage or penalty in any civil, criminal or governmental
litigation or proceeding, or (ii) if not given in the past, might have had a
materially adverse effect on the assets, business or operations of the Company
or any of its subsidiaries as reflected in any of the financial statements
contained in the Memorandum, or (iii) if not continued in the future, might
adversely affect the assets, business, operations or prospects of the Company or
any of its subsidiaries in the future.

                                       9
<PAGE>

         S. The Company has obtained key man life insurance of at least $1
million on the life of Dr. Bruce Kehr in favor of the Company and shall agree to
maintain such policies for a period of at least five years.

         T. MA shall have the right to nominate one (1) director to the
Company's Board of Directors, subject to the consent of management of the
Company, which such consent shall not be unreasonably withheld.

         U. The Company has retained an accounting firm of Bagell Josephs &
Company LLC which is deemed acceptable to MA.

         V. The Company is current in filing all reports, statements and other
materials required to be filed with the Commission pursuant to Rule 144(c)(1)
under the Securities Act to permit holders of Common Stock to sell such
securities in compliance with Rule 144 under the Securities Act.

4.       Certain Covenants and Agreements of the Company.

         The Company covenants and agrees at its expense and without any expense
to MA as follows:

         A. To advise MA of any adverse change in the Company's financial
condition, prospects or business or of any development materially affecting the
Company or rendering untrue or misleading any material statement in the
Memorandum occurring at any time prior to the Closing as soon as the Company is
either informed or becomes aware thereof.

         B. To use its best efforts to cause the Units to be qualified or
registered for sale, or to obtain exemptions from such qualification or
registration requirements, on terms consistent with those stated in the
Memorandum under the securities laws of such jurisdictions as MA shall
reasonably request, provided that such states and jurisdictions do not require
the Company to qualify as a foreign corporation. Qualification, registration and
exemption charges and fees shall be at the sole cost and expense of the Company.
The Company's counsel shall perform the required "Blue Sky" services and the
Company shall pay all expenses and disbursements of the Company's counsel
relating to such "Blue Sky" matters and relating to the Offering.

         C. To provide and to continue to provide to each holder of securities
participating in the Offering, so long as such holder shall remain a security
holder of the Company, for a period ending five (5) years from the Termination
Date, copies of all quarterly and audited annual financial statements prepared
by or on behalf of the Company for public disclosure, other reports prepared by
or on behalf of the Company for public disclosure and all documents delivered to
the Company's stockholders.

                                       10
<PAGE>

         D. To deliver, for a period of five (5) years following the Termination
Date, to MA, in the manner provided in Section 10(B) of this Agreement: (i)
within forty five (45) days after the end of each of the first three quarters of
each fiscal year of the Company, commencing with the first quarter ending after
the Termination Date, a statement of its income for each such quarterly period,
and its balance sheet and a statement of changes in stockholders' equity as of
the end of such quarterly period, all in reasonable detail, certified by its
principal financial or accounting officer; (ii) within ninety (90) days after
the close of each fiscal year, its balance sheet as of the close of such fiscal
year, together with a statement of income, a statement of changes in
stockholders' equity and a statement of cash flow for such fiscal year, such
balance sheet, statement of income, statement of changes in stockholders' equity
and statement of cash flow to be in reasonable detail and accompanied by a copy
of the certificate or report thereon of independent auditors; and (iii) a copy
of all documents, reports and information furnished to its stockholders at the
time that such documents, reports and information are furnished to its
stockholders.

         E. To apply the proceeds of: (i) the Bridge Financing in accordance
with the Note Purchase Agreement and (ii) the Private Placement Offering in
accordance with "Use of Proceeds" in the Memorandum, and not to apply any
proceeds from the Offering to pay any deferred compensation of any current or
former officer or employee of the Company.

         F. To provide MA with as many copies of the Memorandum as MA may
reasonably request.

         G. To grant MA an irrevocable, exclusive right, for a period of three
(3) years commencing on the Note Purchase Closing, to purchase for its account
or to sell for the account of the Company, or any subsidiary of or successor to
the Company any securities of the Company or any such subsidiary or successor
which the Company or any such subsidiary or successor may seek to sell through
an underwriter, placement agent or broker-dealer whether pursuant to
registration under the Act or otherwise (excluding the sale of debt securities
of the Company to commercial banking institutions). Notwithstanding the
foregoing, MA agrees that its exclusive right of first refusal may be purchased
by the Company from MA for a purchase price equal to $100,000 at the election of
the Company, at the time of a future financing (not including the Offering),
whereby upon such election by the Company, MA shall no longer have such
exclusive right. In addition, in the event that MA does not raise at least
$2,000,000 in the Offering, the right of first refusal shall terminate and be
converted into a right to participate in future transactions previously covered
by the right of first refusal. The Company and any such subsidiary or successor
will consult with MA with regard to any such offering and will offer MA the
opportunity to purchase or sell any such securities on terms not more favorable
to the Company or any such subsidiary or successor than it or they can secure
elsewhere. If MA fails to accept such offer within 15 business days after the
mailing of a notice containing such offer by registered mail addressed to MA (5
business days in the event the offer covers a sale under Rule 144), then MA
shall have no further claim or right with respect to the offer contained in such
notice. If, however, the terms of such offer are subsequently modified in any
material respect, the preferential right referred to herein shall apply to such
modified offer as if the original offer had not been made. MA's failure to
exercise its preferential right with respect to any particular offer shall not
affect its preferential rights relative to future offers.

                                       11
<PAGE>

         I. For a period of three (3) years from the date hereof, to not solicit
any offer to buy from or offer to sell to any person introduced to the Company
by MA in connection with the Offering, directly or indirectly, any securities of
the Company or of any other entity, or provide the name of any such person to
any other securities underwriter, broker or dealer or selling agent. In the
event that the Company or any of its affiliates, directly or indirectly,
solicits, offers to buy from or offers to sell to any such person any such
securities, or provides the name of any such person to any other securities
underwriter, broker or dealer or selling agent, and such person purchases such
securities or purchases securities from any other securities underwriter, broker
or dealer or selling agent, the Company shall pay to MA an amount in cash equal
to 10% of the aggregate purchase price of the securities so purchased by, or
sold to, such person. In addition, the Company shall pay MA a fee in cash equal
to five (5%) percent of the gross proceeds received by the Company from the
exercise of any and all Warrants issued in connection with the Offering, payable
on the last business day of each month in which Warrants are exercised.

         J. To not increase the number of options to purchase shares pursuant to
any stock option or other benefit plan or plans providing for the issuance of
options to purchase shares of the Company's common stock without the prior
written consent of the Compensation Committee. No options will be granted and no
existing option plan will be increased and no new option plan will be adopted
without the prior written consent of the Compensation Committee.

         K. The Company represents, warrants and agrees that during the term of
MA's agency hereunder, neither the Company nor any person authorized to act on
the Company's behalf will offer the Units for sale to, or solicit any offers to
purchase the Units from, or except as MA may specifically request, otherwise
approach or negotiate in respect thereof with any other person or persons.
Neither the Company nor any person authorized to act on the Company's behalf
will, directly or indirectly, take any action that would prevent the offering
and sale of the Units from complying with the requirements of all applicable
federal and state securities laws or render unavailable any exemption from the
registration provisions of the Act relied upon in making any such offer or sale,
or the state securities or "blue sky" laws of jurisdictions in which the Units
or the Securities will be offered.

         L. That until all Securities eligible for registration under the Note
Purchase Agreement, the Subscription Agreements and the Placement Agent's
Warrant Agreement have been sold under a registration statement or pursuant to
Rule 144 under the Act, to keep current in filing all reports, statements and
other materials required to be filed with the Commission to permit holders of
such Securities to sell such Securities under Rule 144.

                                       12
<PAGE>

5.       Registration Rights.

         As soon as practicable after the Closing and in any event not later
than forty-five (45) days thereafter, the Company shall prepare and file with
the Commission, a registration statement and such other documents, including a
prospectus, as may be necessary in the opinion of both counsel for the Company
and counsel for the Placement Agent and the holders of the Units, in order to
comply with the provisions of the Securities Act, so as to permit a public
offering and sale of the Shares and the shares of Common Stock issuable upon
exercise of the Warrants and the Placement Agent's Warrants. The costs and
expenses associated with the preparation, filing and prosecution of such
registration statement(s) shall be borne by the Company.

6.       Indemnification.

         A. The Company hereby agrees that it will indemnify and hold MA and
each officer, director, shareholder, employee or representative of MA, and each
person controlling, controlled by or under common control of MA within the
meaning of Section 15 of the Securities Act or Section 20 of the Exchange Act or
the Rules and Regulations, harmless from and against any and all loss, claim,
damage, liability, cost or expense whatsoever (including, but not limited to,
any and all reasonable legal fees and other expenses and disbursements incurred
in connection with investigating, preparing to defend or defending any action,
suit or proceeding, including any inquiry or investigation, commenced or
threatened, or any claim whatsoever or in appearing or preparing for appearance
as a witness in any action, suit or proceeding, including any inquiry,
investigation or pretrial proceeding such as a deposition) to which MA or such
indemnified person of MA may become subject under the Securities Act, the
Exchange Act, the Rules and Regulations, or any other federal or state law or
regulation, common law or otherwise, arising out of or based upon (i) any untrue
statement or alleged untrue statement of a material fact contained in (A)
Section 3 of this Agreement, (B) the Memorandum (except those written statements
relating to MA given by an indemnified person for inclusion therein), (C) any
application or other document or written communication executed by the Company
or based upon written information furnished by the Company filed in any
jurisdiction in order to qualify the Shares under the securities laws thereof,
or any state securities commission or agency; (ii) the omission or alleged
omission from documents described in clauses (A), (B) or (C) above of a material
fact required to be stated therein or necessary to make the statements therein
not misleading; or (iii) the breach of any representation, warranty, covenant or
agreement made by the Company in this Agreement. The Company further agrees that
upon demand by an indemnified person, at any time or from time to time, it will
promptly reimburse such indemnified person for any loss, claim, damage,
liability, cost or expense (including, but not limited to, any and all
reasonable legal fees and other expenses and disbursements incurred in
connection with investigating, preparing to defend or defending any action, suit
or proceeding, including any inquiry or investigation, commenced or threatened,
or any claim whatsoever or in appearing or preparing for appearance as a witness
in any action, suit or proceeding, including any inquiry, investigation or
pretrial proceeding such as a deposition) whatsoever paid by the indemnified
person as to which the Company has indemnified such person pursuant hereto.
Notwithstanding the foregoing provisions of this Paragraph 6(A), any such
payment or reimbursement by the Company of fees, expenses or disbursements
incurred by an indemnified person in any proceeding in which a final judgment by
a court of competent jurisdiction (after all appeals or the expiration of time
to appeal) is entered against MA or such indemnified person as a direct result
of MA or such person's gross negligence or willful misfeasance will be promptly
repaid to the Company.

                                       13
<PAGE>

         B. MA hereby agrees that it will indemnify and hold the Company and
each officer, director, shareholder, employee or representative of the Company,
and each person controlling, controlled by or under common control with the
Company within the meaning of Section 15 of the Securities Act or Section 20 of
the Exchange Act or the Rules and Regulations, harmless from and against any and
all loss, claim, damage, liability, cost or expense whatsoever (including, but
not limited to, any and all reasonable legal fees and other expenses and
disbursements incurred in connection with investigating, preparing to defend or
defending any action, suit or proceeding, including any inquiry or
investigation, commenced or threatened, or any claim whatsoever or in appearing
or preparing for appearance as a witness in any action, suit or proceeding,
including any inquiry, investigation or pretrial proceeding such as a
deposition) to which the Company or such indemnified person of the Company may
become subject under the Securities Act, the Exchange Act, the Rules and
Regulations, or any other federal or state law or regulation, common law or
otherwise, arising out of or based upon (i) the conduct of MA or its officers,
employees or representatives in its acting as placement agent for the Offering;
(ii) the breach of any representation, warranty, covenant or agreement made by
MA in this Agreement or (iii) the untrue statement or alleged untrue statement
or omission or alleged admission made in the Memorandum in reliance upon and in
strict conformity with written information furnished by MA specifically for use
in preparation of the Memorandum.

         C. Promptly after receipt by an indemnified party of notice of
commencement of any action covered by Section 6(A) or 6(B), the party to be
indemnified shall, within five (5) business days, notify the indemnifying party
of the commencement thereof; the omission by one indemnified party to so notify
the indemnifying party shall not relieve the indemnifying party of its
obligation to indemnify any other indemnified party that has given such notice
and shall not relieve the indemnifying party of any liability outside of this
indemnification if not materially prejudiced thereby. In the event that any
action is brought against the indemnified party, the indemnifying party will be
entitled to participate therein and, to the extent it may desire, to assume and
control the defense thereof with counsel chosen by it which is reasonably
acceptable to the indemnified party. After notice from the indemnifying party to
such indemnified party of its election to so assume the defense thereof, the
indemnifying party will not be liable to such indemnified party under such
Section 6(A) or 6(B) for any legal or other expenses subsequently incurred by
such indemnified party in connection with the defense thereof, but the
indemnified party may, at its own expense, participate in such defense by
counsel chosen by it, without, however, impairing the indemnifying party's
control of the defense. Subject to the proviso of this sentence and
notwithstanding any other statement to the contrary contained herein, the
indemnified party or parties shall have the right to choose its or their own
counsel and control the defense of any action, all at the expense of the
indemnifying party if, (i) the employment of such counsel shall have been
authorized in writing by the indemnifying party in connection with the defense
of such action at the expense of the indemnifying party, or (ii) the
indemnifying party shall not have employed counsel reasonably satisfactory to
such indemnified party to have charge of the defense of such action within a
reasonable time after notice of commencement of the action, or (iii) such
indemnified party or parties shall have reasonably concluded that there may be
defenses available to it or them which are different from or additional to those
available to one or all of the indemnifying parties (in which case the
indemnifying parties shall not have the right to direct the defense of such
action on behalf of the indemnified party or parties), in any of which events
such fees and expenses of one additional counsel shall be borne by the
indemnifying party; provided, however, that the indemnifying party shall not, in
connection with any one action or separate but substantially similar or related
actions in the same jurisdiction arising out of the same general allegations or
circumstance, be liable for the reasonable fees and expenses of more than one
separate firm of attorneys at any time for all such indemnified parties. No
settlement of any action or proceeding against an indemnified party shall be
made without the consent of the indemnifying party.

                                       14
<PAGE>

7.       Payment of Expenses.

         Whether or not the Offering is successfully completed, the Company
hereby agrees to bear all of the expenses in connection with the Offering,
including, but not limited to the following: due diligence expenses, filing
fees, printing and duplicating costs, advertisements, postage and mailing
expenses with respect to the transmission of offering material, registrar and
transfer agent fees, escrow agent fees and expenses, fees of the Company's
counsel and accountants, fees and expenses of MA's counsel, issue and transfer
taxes, if any, and "Blue Sky" counsel fees and expenses. It is agreed that the
Company's counsel shall perform the required Blue Sky legal services. In this
connection, Blue Sky applications for registration of the Units or exemption
therefrom shall be made in such states and jurisdictions as shall be requested
by MA, provided that such states and jurisdictions do not require the Company to
qualify as a foreign corporation.

8.       Conditions of the Closing.

         The Closing shall be held at the offices of MA or its counsel. The
obligations of MA hereunder shall be subject to the continuing accuracy of the
representations and warranties of the Company herein as of the date hereof and
as of the Closing with respect to the Company as if it had been made on and as
of the Closing; the accuracy on and as of the Closing of the statements of the
officers of the Company made pursuant to the provisions hereof; and the
performance by the Company on and as of the Closing of its covenants and
obligations hereunder and to the following further conditions:

         A. At the Closing, MA shall receive the opinion of Snow Becker Krauss
P.C., counsel to the Company, dated as of the date of the Closing, which opinion
shall be in form and substance reasonably satisfactory to counsel for MA and
containing the usual assumptions and limitations, to the effect that:

                                       15
<PAGE>

                  (i) The execution, delivery and performance of each of this
Agreement, the Note Purchase Agreement, the Placement Agent's Warrant Agreement,
the Consulting Agreement, the M&A Agreement, the Subscription Agreements and the
Escrow Agreement has been duly and validly authorized by the Company and,
assuming due authorization, execution and delivery by each other party thereto,
each such agreement is a valid and binding agreement of the Company, enforceable
in accordance with its respective terms. The Placement Agent's Warrants
constitute valid and binding obligations of the Company to issue and sell, upon
exercise thereof and payment therefore in accordance with their respective
terms, the number and type of securities of the Company called for thereby. The
Securities to be issued and sold by the Company pursuant to the Memorandum, the
Note Purchase Agreement, the Placement Agent's Warrant Agreement, this Agreement
and the Subscription Agreements have been duly authorized and, when issued and
paid for in accordance with the Memorandum, the Note Purchase Agreement, the
Placement Agent's Warrant Agreement, this Agreement and the Subscription
Agreements, will be validly issued, fully paid and non-assessable; such
securities are not and will not be subject to the preemptive rights of any
stockholder of the Company pursuant to the Company's certificate of
incorporation or, to such counsel's knowledge, any agreement of the Company with
any stockholder; and all corporate action required to be taken for the
authorization, issuance and sale of such securities has been duly and validly
taken by the Company. The Securities conform with respect to legal matters in
all material respects to the description thereof contained in the Memorandum.

                  (ii) Each of the Company and its subsidiaries is validly
existing as a corporation in good standing under the laws of its state of
incorporation. Each of the Company and its subsidiaries is qualified to do
business and is in good standing as a foreign corporation in each jurisdiction
in which its ownership or leasing of any properties or the character of its
operations (as described in the Memorandum) requires such qualification, except
where the failure to so qualify would not have a material adverse effect on the
business, properties or operations of the Company and its subsidiaries (as
described in the Memorandum) taken as a whole. Except as described in the
Memorandum, each of the Company and its subsidiaries has all requisite corporate
power and authority to own or lease its properties and conduct its business (or
proposed business) as described in the Memorandum.

                  (iii) To such counsel's knowledge, the holders thereof have no
preemptive rights with respect thereto pursuant to the Company's certificate of
incorporation or, to such counsel's knowledge, any agreement of the Company with
any stockholder, and are not subject to personal liability solely by reason of
being security holders; and none of such securities was issued in violation of
the preemptive rights of any holders of any security of the Company pursuant to
the Company's certificate of incorporation or, to such counsel's actual
knowledge, any agreement of the Company with any stockholder. The Company has
20,000,000 shares of authorized Common Stock, of which 9,165,585 are issued and
outstanding as of the date hereof and 4,500,000 shares of preferred stock, none
of which are issued and outstanding as of the date hereof.

                                       16
<PAGE>

                  (iv) To such counsel's knowledge, there is no litigation or
governmental proceeding, pending or threatened against, the Company or any of
its subsidiaries or any of their assets, except as set forth in the Memorandum.

                  (v)(a) To such counsel's knowledge (without regard to the
transactions contemplated by this Agreement), neither the Company nor any of its
subsidiaries is in breach of, or in default under, any term or provision of any
material indenture, mortgage, deed of trust, lease, note, loan or credit
agreement or any other material agreement or instrument evidencing an obligation
for borrowed money, or any other material agreement or instrument to which it is
a party or by which it or any of its properties may be bound or affected (other
than any breach of default under any financial tests and covenants as to which
they express no opinion), (b) To such counsel's knowledge (without regard to the
transactions contemplated by this Agreement), neither the Company nor any of its
subsidiaries is in violation of any provision of its charter or bylaws or in
violation of any franchise, license, permit, judgment, decree or order, or in
violation of any statute, rule or regulation. (c) To such counsel's knowledge,
neither the execution and delivery of this Agreement, the Note Purchase
Agreement, the Escrow Agreement, the Placement Agent's Warrant Agreement, the
Consulting Agreement, the M&A Agreement or the Subscription Agreements nor the
issuance and sale or delivery of the Securities nor the consummation of any of
the transactions contemplated herein or in the Note Purchase Agreement, the
Subscription Agreements or the Placement Agent's Warrant Agreement, nor the
compliance by the Company with the terms and provisions hereof or thereof, has
conflicted with or will conflict with, or has resulted in or will result in a
breach of, any of the terms and provisions of, or has constituted or will
constitute a default under, or will give to others any right of termination,
amendment, acceleration or cancellation of, or has resulted in or will result in
the creation or imposition of any lien, charge or encumbrance upon any property
or assets of the Company or any of its subsidiaries pursuant to, the terms of
any material indenture, mortgage, deed of trust, note, loan or credit agreement
or any other material agreement or instrument evidencing an obligation for
borrowed money, or any other material agreement or instrument to which the
Company or any of its subsidiaries may be bound or to which any of the property
or assets of the Company or any of its subsidiaries is subject except (i) where
such default, lien, charge, encumbrance or other occurrence would not have a
material adverse effect on the Company or any of its subsidiaries and (ii) as
described in the Memorandum and (iii) conflicts with any financial tests and
covenants as to which they express no opinion; nor will such action result in
any violation of the provisions of the charter or the bylaws of the Company or
any of the Subsidiaries or, assuming the due performance by MA of its
obligations hereunder, any statute, rule or regulation that is applicable to the
Company or any of its subsidiaries and that is in such counsel's experience
normally applicable to transactions of the type contemplated by this Agreement
(other than Blue Sky laws), or, to such counsel's knowledge, any order of any
court or of any foreign, federal, state or other regulatory authority or other
government body having jurisdiction over the Company or any of its subsidiaries.

                  (vi) Assuming that each purchaser of the Securities is an
Accredited Investor, that the representations made by the Company and MA in this
Agreement and the Note Purchase Agreement are true and correct at all times
during the Offering Period and at the time of each of the Note Purchase Closing
and the Closing, that MA has complied with the provisions of this Agreement and
of Section 502(c) of Regulation D and that a Form D will be filed in accordance
with the provisions of Section 503 of Regulation D, no registration under the
Securities Act is required in connection with the sale and issuance of any of
the Securities by the Company.

                                       17
<PAGE>

In rendering such opinion, such counsel may rely, as to matters of fact, to the
extent they deem proper, on certificates and written statements of responsible
officers of the Company and certificates or other written statements of officers
of departments of various jurisdictions having custody of documents respecting
the corporate existence or good standing of the Company, provided that copies of
any such statements or certificates shall be delivered to MA's counsel.

         Such counsel shall state that it has participated in conferences with
officers and other representatives of the Company during which the contents of
the Memorandum were discussed.

         B. At or prior to the Closing, counsel for MA shall have been furnished
such documents, certificates and opinions as they may reasonably require for the
purpose of enabling them to review or pass upon the matters referred to in this
Agreement, the Note Purchase Agreement and the Memorandum, or in order to
evidence the accuracy, completeness or satisfaction of any of the
representations, warranties or conditions herein contained.

         C. At and prior to the Closing, (i) there shall have been no material
adverse change nor development involving a prospective change in the condition
or prospects or the business activities, financial or otherwise, of the Company
or any of its subsidiaries, from the latest dates as of which such condition is
set forth in the Memorandum; (ii) there shall have been no transaction, not in
the ordinary course of business, entered into by the Company or any of its
subsidiaries which has not been disclosed in the Memorandum or to MA in writing;
(iii) neither the Company nor any of its subsidiaries shall be in default under
any provision of any instrument relating to any outstanding indebtedness for
which a waiver or extension has not been otherwise received; (iv) except as set
forth in the Disclosure Schedule, the Company shall not have issued any
securities (other than those set forth in the Disclosure Schedule and the Note
Purchase Agreement) or declared or paid any dividend or made any distribution of
its capital stock of any class and there shall not have been any change in the
indebtedness (long or short term) or liabilities or obligations of the Company
(contingent or otherwise); (v) no material amount of the assets of the Company
or any of its subsidiaries shall have been pledged or mortgaged, except as
indicated in the Disclosure Schedule; and (v) no action, suit or proceeding, at
law or in equity, against the Company or any of its subsidiaries or affecting
any of its properties or businesses shall be pending or threatened before or by
any court or federal or state commission, board or other administrative agency,
domestic or foreign, wherein an unfavorable decision, ruling or finding could
materially adversely affect the businesses, prospects or financial condition or
income of the Company or any of its subsidiaries, except as set forth in the
Memorandum.

         D. At the Closing, MA shall have received a certificate of the Company
signed by its Chief Executive Officer, dated as of the date of the Closing, to
the effect that the conditions set forth in subparagraph (C) above have been
satisfied and that, as of the date of the Closing, the representations and
warranties of the Company set forth herein are true and correct.

                                       18
<PAGE>

         E. At the Closing, the Company shall have duly executed and delivered
the appropriate amount and designation of Shares to MA as agent for the
respective holders thereof.

         F. At or prior to the Closing, the Company shall deliver a duly
executed, legally binding Placement Agent's Warrant Agreement and at the Closing
the Company shall duly and validly issue Placement Agent's Warrants to purchase
the number of Shares sold by the Company.

         G. At or prior to the Closing, the Company will enter into a three (3)
year agreement with MA (the "Consulting Agreement") pursuant to which, among
other things, the Company shall employ MA as its financial consultant. MA will
be compensated for such services as set forth in the Consulting Agreement.

         H. At or prior to the Closing, the Company will enter into a three (3)
year agreement with MA (the "M&A Agreement") pursuant to which, among other
things, the Company shall employ MA as its investment banker. MA will be
compensated for such services as set forth in the M&A Agreement.

9.       Termination.

         This Agreement shall terminate if the Closing specified in Section
1(F)(ii) does not take place on or before the seventh (7th) business day
following the Termination Date or as soon thereafter as the funds received from
subscriptions have cleared the banking system in the normal course of business.
Either MA or the Company may terminate the Offering in its sole discretion prior
to the Closing. In the event that the Company determines to terminate the
Offering from and after the date hereof through the end of the Offering Period
for any reason other than MA's breach of the terms of this Agreement, and MA is
willing to proceed with the Offering, then the Company shall immediately pay to
MA a termination fee (the "Termination Fee") equal to $250,000 and the amount of
MA's verifiable out-of-pocket expenses. Upon such termination by the Company,
all subscription documents and payments for the Shares not previously delivered
to the purchasers thereof, without interest thereon or deduction therefrom,
shall be returned to the respective subscribers, MA shall have no further
obligation to the Company, and the Company shall have no obligation to MA other
than payment of the Termination Fee and MA's verifiable out-of-pocket expenses.

10.      Miscellaneous.

         A. This Agreement may be executed in any number of counterparts, each
of which shall be deemed to be an original, but all which shall be deemed to be
one and the same instrument.

                                       19
<PAGE>

         B. Any notice required or permitted to be given hereunder shall be
given in writing and shall be deemed effective when deposited in the United
States mail, postage prepaid, or when received if delivered personally or by
facsimile confirmed transmission, addressed as follows:

         To MA:

                  Meyers Associates, L.P.
                  45 Broadway
                  New York, New York 10006
                  Fax:  (212) 742-4259
                  Attention: Bruce Meyers

         with a copy to:

                  Morrison Cohen Singer & Weinstein, LLP
                  750 Lexington
                  New York, New York  10022
                  Fax:  (212) 735-8708
                  Attention:  Robert H. Cohen, Esq.

         To the Company:

                  InforMedix Holdings Inc.
                  Georgetowne Park
                  5880 Hubbard Drive
                  Rockville, Maryland 20852
                  Fax:  (301)
                  Attention:  Dr. Bruce A. Kehr

         with a copy to:

                  Snow Becker Kraus P.C.
                  605 Third Avenue
                  New York, New York  10158
                  Fax:  (212) 949-7052
                  Attention:  Elliot H. Lutzker, Esq.

or to such other address of which written notice is given to the others.

                                       20
<PAGE>

         C. This Agreement shall be governed by and construed in all respects
under the laws of the State of New York. Any suit, action, proceeding or
litigation arising out of or relating to this Agreement shall be brought and
prosecuted in such federal or state court or courts located within the State of
New York as provided by law. The parties hereby irrevocably and unconditionally
consent to the jurisdiction of each such court or courts located within the
State of New York and to service of process by registered or certified mail,
return receipt requested, or by any other manner provided by applicable law, and
hereby irrevocably and unconditionally waive any right to claim that any suit,
action, proceeding or litigation so commenced has been commenced in an
inconvenient forum.

         D. This Agreement and the other agreements referenced herein contain
the entire understanding between the parties hereto and may not be modified or
amended except by a writing duly signed by the party against whom enforcement of
the modification or amendment is sought.

         E. If any provision of this Agreement shall be held to be invalid or
unenforceable, such invalidity or unenforceability shall not affect any other
provision of this Agreement.

                  [REMAINDER OF PAGE LEFT INTENTIONALLY BLANK]

                                       21
<PAGE>

         IN WITNESS WHEREOF, the parties hereto have executed this Agreement as
of the date first written above.

                                        INFORMEDIX HOLDINGS INC.

                                        By:____________________________________
                                               Name:  Dr. Bruce A. Kehr
                                               Title:  Chief Executive Officer

MEYERS ASSOCIATES, L.P.

By:___________________________
         Name:  Bruce Meyers
         Title:  President

                                       22AMENDMENT #1 TO THE EMPLOYMENT AGREEMENT
                   BETWEEN INFORMEDIX AND BRUCE A. KEHR, M.D.

         This Amendment # 1 to the Employment  Agreement Between  InforMedix and
Bruce A. Kehr,  M.D. (the  "Amendment  #1") dated as of the 5th day of February,
2001 and  effective  on  January  1, 2001  (the  "Effective  Date")  is  between
InforMedix,  Inc., a Delaware corporation ("Employer" or the "Corporation") with
offices at 5880 Hubbard Dr.,  Rockville,  MD 20852-4821 and Bruce A. Kehr,  M.D.
residing at 9429 Holbrook Lane, Potomac, Maryland, 20854 ("Employee").

WITNESSETH:

          WHEREAS, Employer has previously employed the Employee as its Chairman
 of the Board of Directors  ("Chairman")  and Chief  Executive  Officer  ("CEO")
 under and pursuant to an Employment Agreement with Employee dated as of January
 1, 2000 (the "Employment Agreement"); and,

          WHEREAS,  both  the  Employer  and  the  Employee  wish to  amend  the
Employment Agreement and have the Employee continue employment with the Employer
upon the terms and conditions set forth in this Amendment # 1.

         NOW,   THEREFORE,   in   consideration  of  the  mutual  covenants  and
obligations  hereinafter  set forth,  and the  consideration,  the  receipt  and
sufficiency  of 'which is hereby  acknowledged,  Employer and Employee  agree as
follows.

1.       Effect of this Amendment #1.

         A.       All of the terms and conditions set forth in this Amendment #1
                  shall:

                  (1)      be  effective  as of the  Effective  Date,  unless  a
                           different  date is  specifically  referred to in this
                           Amendment #1; and

         (2)      supersede  and  replace  those   sections  of  the  Employment
                  Agreement, which they specifically change.

         B.       All other terms and  conditions  not  specifically  changed by
                  this  Amendment  # 1 shall  remain in full force and effect in
                  accordance  with the terms and  conditions  of the  Employment
                  Agreement.

<PAGE>

2.       Compensation; Reimbursement.

         Section  4  of  the  Employment   Agreement,   entitled   Compensation;
         Reimbursement.,  is replaced in its  entirety by this Section 2 of this
         Amendment #1, entitled Compensation; Reimbursement.

         A.       Commencing on the Effective  Date,  Employer (or at Employer's
                  option,  any subsidiary or affiliate thereof) shall pay to the
                  Employee an annual salary of $200,000.00 (two hundred thousand
                  dollars),  with a minimum of $40,000 (forty thousand  dollars)
                  to be paid in cash (the "Salary").  The Salary will be paid in
                  biweekly installments.

         B.       If it is determined by the Executive Committee of the Board of
                  Directors of Employer (the "Executive  Committee")  that there
                  are  insufficient  funds to pay any  portion  of the Salary in
                  cash,  then the portion of the Salary not paid in cash,  up to
                  the full  amount  of the  Salary,  will be paid in the form of
                  non-qualified  stock  options  of  Employer,   as  defined  in
                  Employer's  Omnibus  Stock Plan  (<<Plan"),  with an  exercise
                  price per share of $1.00 (one dollar),  which vest immediately
                  when granted,  and become  exercisable one year after the date
                  of each grant (the "Salary Options").

                  (1)      The number of shares  subject  to the Salary  Options
                           (the "Salary Option  Share(s)") will be determined by
                           dividing  the  amount of the Salary not to be paid in
                           cash,  by the per share  price of  InforMedix  Common
                           Stock on the date of grant of the Salary  Options (on
                           the Effective Date of this Amendment # 1 it is $10.00
                           [ten dollars] per share), less the $1.00 (one dollar)
                           exercise price, or $9.00 (nine dollars).

                  (2)      For example,  were  $160,000.00  (one  hundred  sixty
                           thousand  dollars)  of Salary not to be paid in cash,
                           then,   Salary   Options   to   purchase   17,777.777
                           (seventeen  thousand,   seven  hundred  seventy-seven
                           point seven seven seven)  Salary  Option Shares would
                           be granted.

                  (3)      If Employer  sells,  or otherwise cause to be issued,
                           any  shares  of  InforMedix  Common  Stock,  or other
                           instruments convertible into InforMedix Common Stock,
                           for less than  $10.00  (Ten  Dollars)  per share (the
                           "Revised Price Per Share"), then Employer shall issue
                           to Purchaser, additional Salary Option Shares so that
                           the  Salary  Option  Shares  equal the  amount of the
                           Salary not to be paid in cash, divided by the Revised
                           Price Per Share.

<PAGE>

         C.       Employer,  at the  election  of the  Board of  Directors,  may
                  exercise a call on some or all of the issued,  but unexercised
                  Salary Options held by Employee as of the date of such call (a
                  "Call"),  and  purchase  those Salary  Options  from  Employee
                  within 60  (sixty)  days of a Call,  at a  purchase  price per
                  Salary Option Share equal to the  then-effective  market price
                  per share of  InforMedix  Common  Stock,  but in no event less
                  than $10.00 (Ten Dollars) per share,  less the $1.00  exercise
                  price,  and  subject  to the  terms and  conditions  set forth
                  below.

                  (1)      At any time  during a  calendar  year,  Employer  may
                           exercise  a  Call  to  purchase  some  or  all of the
                           unexercised  Salary Options earned by Employee at any
                           time in that  calendar  year, up to and including the
                           date of the exercise of a Call.

                  (2)      Up to and including March 31st of any year,  Employer
                           may  exercise a Call to  purchase  some or all of the
                           unexercised  Salary Options earned by Employee at any
                           time in the preceding calendar year.

                  (3)      Nothing  in  this   Subsection   of  the   Employment
                           Agreement  shall  authorize  or  permit  Employer  to
                           purchase  InforMedix  Common  Stock owned by Employee
                           which had  previously  been subject to Salary Options
                           of Employee,  and which had previously been exercised
                           by Employee and converted to InforMedix Common Stock.

3.       Performance-Based Stock Options and Vesting.

         Section 6 of the Employment Agreement, entitled Performance-Based Stock
         Options and Vesting.,  is replaced in its entirety by this Section 3 of
         this  Amendment  #1,  entitled   Performance-Based  Stock  Options  and
         Vesting.

         A.       Employer hereby issues to the Employee upon the Effective Date
                  of this  Amendment #1, 35,001  (thirty-five  thousand and one)
                  performance-based  stock options to purchase InforMedix Common
                  Stock, in the form of  non-qualified,  incentive stock options
                  of Employer, as defined in the Plan, with an exercise price of
                  $10.00  (ten  dollars)  per  share,  which  shall  vest and be
                  exercisable according to the schedule below,  exercisable upon
                  the vesting date of each grant,  and otherwise  subject to the
                  terms and  conditions  of this Section 3. of Amendment #1 (the
                  "'PB Options").

         B.       The PB Options to purchase  InforMedix  Common Stock will vest
                  based upon the attainment of  pre-determined  and pre-assigned
                  performance targets, as determined by the Board of Directors.

<PAGE>

         C.       The PB Options will be for a three-year period, with one-third
                  of the  shares  subject  to the PB  Options  (the  "PB  Option
                  Share(s)"),  vesting in each of the three  years of each grant
                  (a "Grant").

         D.       The number of PB Option  Shares  subject to the PB Options for
                  each Grant, will be 11,667, which will be eligible for vesting
                  in each of the three (3) years of each Grant.

         E.       After the date that the  Employee  ceases to be an employee or
                  director of Employer,  no PB Options or PB Option Shares shall
                  vest,  except as  specifically  provided in Section 5. of this
                  Amendment # 1.

4.       Acceleration of Vesting of Salary Options and PB Options.

         Subsection 7.E. of the Employment Agreement is hereby superseded by the
         following, which shall replace that Subsection in its entirety.

         A.       The Salary  Options and the PB Options  shall  accelerate  and
                  become one hundred percent vested and immediately exercisable,
                  upon  the  occurrence  of  any  of  the  following  conditions
                  (collectively   referred  to  as  the   "Accelerated   Vesting
                  Conditions"):

         (1)      upon the dissolution or liquidation of the Company; or

         (2)      upon a reorganization, merger, or consolidation of the Company
                  as a result of which the  outstanding  securities of the class
                  of securities  then subject to the Options are changed into or
                  exchanged  for  cash  or  property  or  securities  not of the
                  Company's issue; or

         (3)      any combination thereof;

         (4)      upon a sale  of  substantially  all  of  the  property  of the
                  Company to, or the  acquisition of a majority of the shares of
                  InforMedix   Common  Stock  then   outstanding   by,   another
                  Corporation or person; or

         (5)      a Termination without Cause of the Employee.

<PAGE>

5.       Adjustment of Agreement and Amendment #1 Options.

         A new Section 7 A is added to the Employment Agreement as follows.

         7A.      Adjustment of Agreement and Amendment #1 Options.

         A.       In the event that  InforMedix  issues shares of its InforMedix
                  Common Stock or rights, options or warrants for, or securities
                  convertible or exchangeable  into InforMedix  Common Stock, to
                  any  person  or  entity  other  than  Employee   (collectively
                  referred to as a "Third Party"), entitling such Third Party to
                  subscribe for or purchase shares of InforMedix Common Stock at
                  a price per share  that is lower at the  record  date than the
                  exercise  price of the Base Salary  Options and Option  Shares
                  issued  under the  Employment  Agreement,  and Salary  Options
                  and/or  the  PB  Options   issued  under  this   Amendment  #1
                  (collectively  referred to as the  "Agreement and Amendment #1
                  Options"  and such event  referred to as a "Dilutive  Event"),
                  the exercise  price of the Agreement and Amendment # I Options
                  shall be reduced to the  exercise  price or share price of the
                  Dilutive Event.

                  (1)      The new number of shares of  InforMedix  Common Stock
                           purchasable  upon the exercise of the  Agreement  and
                           Amendment   #1  Options   shall  be   determined   by
                           multiplying  the old number of shares  purchasable by
                           the Agreement  and Amendment # 1 Options,  by the old
                           exercise  price of the  Agreement  and  Amendment # 1
                           Options,  divided  by the new  exercise  price of the
                           Agreement and Amendment # 1 Options.

                  (2)      A Dilutive  Event will not be deemed to have occurred
                           for the sale or  issuance  of  shares  of  InforMedix
                           Common  Stock  (including  options) to  employees  of
                           InforMedix,  that are  approved by the Board,  or the
                           exercise   of   currently   authorized   options  and
                           warrants.

         B.       The number of  Agreement  and  Amendment  #1  Options  will be
                  adjusted  in the same  manner as other  shares  of  InforMedix
                  Common  Stock issued and  outstanding  - as of the date of the
                  Employment  Agreement  for the Base Salary  Options and Option
                  Shares issued under the  Employment  Agreement,  and as of the
                  Effective Date of this Amendment #1 for the Salary Options and
                  the PB Options  issued under this Amendment # 1 - in the event
                  of, but not limited to, any of the following,  which occur and
                  which affect the InforMedix Common Stock: stock split; reverse
                  stock split; recapitalization; and/or other adjustment.

<PAGE>

         C.       For as long as the stock of InforMedix has not been registered
                  under the United States Federal  securities  laws and/or state
                  securities laws, the Agreement and Amendment #1 Options cannot
                  be transferred or sold to another  individual,  corporation or
                  entity unless permitted under the InforMedix  Investors Rights
                  Agreement, or agreed upon by a majority of the Board, and then
                  only in compliance with applicable laws and regulations.

         D.       After the stock of InforMedix  has been  registered  under the
                  United States Federal  securities laws and/or state securities
                  laws,  the  shares  issued  as a  result  of  exercise  of the
                  Agreement and Amendment #1 Options may be transferred or sold,
                  but only in compliance  with:  the security laws of the United
                  States of America; the security laws of applicable states; all
                  other applicable laws and regulations;  any other restrictions
                  placed on the transferability of the Agreement and Amendment #
                  1  Options  and  agreed  to  by  the  Board  of  Directors  of
                  InforMedix,   including  but  not  limited  to  those  by  the
                  underwriter  or other  investment  banker with  respect to the
                  public  offer,   sale,   and/or   transfer  of  the  stock  of
                  InforMedix, especially those shares of stock held by officers,
                  directors,   and  insiders  of   InforMedix;   and  any  other
                  restrictions  placed on the transferability of stock agreed to
                  by the directors of  InforMedix.  Employee  further  agrees to
                  have a legend placed on the certificates for the Agreement and
                  Amendment #1 Options  reflecting any of the provisions of this
                  Amendment #1 and the Agreement.

6.       Termination of Employment.

         Subsections  8.C.  and  8.D.of  the  Employment  Agreement  are  hereby
         superseded by the following,  which shall replace those  Subsections in
         their entirety.

         C.       Upon a  Constructive  Termination  and/or Death or  Disability
                  Termination, as defined in the. Employment Agreement, Employee
                  shall be entitled  to the  vesting of the PB Options  only for
                  the year of such  termination,  under the terms and conditions
                  as set forth in this Section 3 of this  Amendment #1.  Nothing
                  in this Subsection  shall limit or restrict the vesting of the
                  Salary Options and/or Salary Shares for Employee.

         D.       Termination With Cause.

                  Upon the  termination of the Employee's  employment  under the
                  Employment  Agreement  pursuant to a  Termination  With Cause,
                  neither the Employee nor the Employee's  beneficiary or estate
                  shall have any further rights or claims against Employer under
                  this Amendment #1, except

                  (1)      to receive the following:

                           (a)      the unpaid  portion  of the Base  Salary and
                                    any Salary  Options  computed  on a pro rata
                                    basis to the date of termination; and

                           (b)      reimbursement for any expenses for which the
                                    Employee  shall  not have  theretofore  been
                                    reimbursed; and

<PAGE>

                           (c)      payment of all unused  vacation time accrued
                                    through the date of termination; and

                  (2)      less the following:

                           (a)      all amounts owing to Employer; and

                           (b)      the    total    value   of   any    possible
                                    misappropriations ITom Employer.

                  (3)      In addition, on the date of a Termination With Cause:

                           (a)      all  unvested PB Options  shall  immediately
                                    terminate; and

                           (b)      all  unvested  warrants  and other  unvested
                                    rights  granted to the  Employee to purchase
                                    or  otherwise  receive  stock  of  Employer,
                                    shall immediately terminate; and

                           (c)      all vested but  unexercised  Salary  Options
                                    and  PB  Options  shall  become  immediately
                                    exercisable,  and  Employee  shall  have the
                                    right to exercise all, or a portion of, such
                                    vested but unexercised Salary Options and PB
                                    Options,  subject to the following terms and
                                    conditions:

                                    [1]      the Employee shall have twenty (20)
                                             days from the date of a Termination
                                             With Cause to give  written  notice
                                             to  Employer   of  the   Employee's
                                             intention  to  exercise  all,  or a
                                             portion   of,   such   vested   but
                                             unexercised  Salary  Options and PB
                                             Options; and

                                    [2]      within  forty  (40)  days  from the
                                             date of a  Termination  With Cause,
                                             Employee must:

                                    [a]      exercise all, or a portion of, such
                                             vested   but   unexercised   Salary
                                             Options and PB Options; and

                                    [b]      make  payment  in full to  Employer
                                             in.  cash,  cash  equivalents,   or
                                             other  immediately  available funds
                                             for  the  exercise  of  the  Salary
                                             Options and PB Options; and

<PAGE>

                                    [c]      otherwise   complete   the   entire
                                             settlement process for the exercise
                                             of  all,  or  a  portion  of,  such
                                             vested   but   unexercised   Salary
                                             Options and PB Options.

                                    [3]      Any    portion    of   vested   but
                                             unexercised  Salary  Options and PB
                                             Options,  which  are not  exercised
                                             under and pursuant to the terms and
                                             conditions   of   this   Subsection
                                             B.(3)(c)     shall      immediately
                                             terminate.

7.       General Provisions.

         A.       This  Amendment #1 contains the entire  understanding  between
                  the  parties  and   supersedes   any  prior  written  or  oral
                  agreements,  understandings,  term  sheets.  or other  between
                  them,  with respect to the matters  covered by this  Amendment
                  #1.

         B.       This  Amendment  # 1 and any or all  terms  hereof  may not be
                  changed, waived,  discharge~ or terminated orally, but only by
                  way of an  instrument  in writing  signed by both Employer and
                  Employee.

         C.       Employee  acknowledges  that this Amendment #1 was made by the
                  parties in  Maryland  and shall be  governed  and  enforced in
                  accordance with the laws of Maryland, without reference to the
                  conflicts  of laws  of the  State  of  Maryland  or any  other
                  jurisdiction. Employee acknowledges that the state and federal
                  courts  of  Maryland  shall  be the  exclusive  for a for  the
                  resolution of any disputes  concerning  this  Amendment # 1 or
                  concerning  Employee's employment with the Company and that he
                  agrees to submit to the jurisdiction of those courts.

         D.       Employee acknowledges that, if Employee breaches any provision
                  of this Amendment #1, the Company will be irreparably  harmed,
                  that   monetary   damages  alone  may  not  be  sufficient  to
                  adequately  protect the Company ftom such breach, and that, in
                  addition to any other remedy, the Company shall be entitled to
                  recover all expenses  incurred in enforcing these  provisions,
                  including   attorneys'   fees  and  court  costs,   and  to  a
                  preliminary and permanent injunction enjoining such breach.

<PAGE>

         E.       If any  portion  of this  Amendment  # 1 shall  be found to be
                  invalid or contrary to public policy, the same may be modified
                  or  stricken  by a Court  of  competent  jurisdiction,  to the
                  extent necessary to allow the Court to enforce such provisions
                  in a manner which is as consistent with the original intent of
                  the provisions as possible.  The striking or  modification  by
                  the  Court of any  provision  shall  not have  the  effect  of
                  invalidating the Amendment # 1 as a whole. In addition, if any
                  valid  federal  or  state  law or final  determination  of any
                  administrative  agency  or  court  of  competent  jurisdiction
                  affects any provision of this Amendment #1, then the provision
                  or provisions so affected  shaH  automatically  be modified to
                  conform  to  the  law  or  determination  and  otherwise  this
                  Amendment # 1 shall continue in full force and effect.

         F.       The section  headings  contained in this Amendment # 1 are for
                  reference  purposes  only and shall not  affect in any way the
                  meaning or interpretation of this Amendment # 1.

         G.       This  Amendment  #1 is personal in its nature and Employer and
                  Employee shall not,  without the consent of the other,  assign
                  or transfer  this  Amendment  #1 or any rights or  obligations
                  under this Employment Agreement;  provided,  however, that the
                  provisions  hereof  shall  inure  to the  benefit  of,  and be
                  binding  upon the  parties  and  their  respective  executors,
                  administrators,  personal representatives,  heirs, assigns and
                  successors  in  interest,  and  each  successor  of  Employer,
                  whether  by  merger,   consolidation,   transfer   of  all  or
                  substantially all assets, or otherwise and the heirs and legal
                  representatives of the Employee.

         H.       The  obligations  of  the  General  Provisions  Section  shall
                  survive the termination or expiration of this Amendment #1.

         I.       Both  parties  have read the  foregoing  Amendment  # 1 in its
                  entirety  and  voluntarily  agree  to  each of its  terms  and
                  conditions with full knowledge of such terms and conditions

         J.       Employer and Employee  acknowledge  and agree that any and all
                  grants of Salary Options and PB Options under this Amendment #
                  1 are  made  pursuant  to  the  authorization  and  terms  and
                  conditions of the Employer's Omnibus Stock Plan and Restricted
                  Stock  Agreement  which  shall  be  controlling  except  where
                  expressly modified in this Amendment #1.

<PAGE>

           IN WITNESS WHEREOF,  the parties have duly executed this Amendment #1
as of the date first above written.

 INFORMEDIX, INC. ("Corporation")

 By:
     ----------------------------------             ----------------------------
     Robert H. Benson, Ph.D., President             Date

 EMPLOYEE ("Employee")

By:
    -----------------------------------             ----------------------------
      Bruce A. Kehr, M.D.                           Date

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00060-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00060-of-00352.parquet"}]]